enVVeno Medical Corporation Common Stock (NVNO)

Price$10.21

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-22.13%

Price vs S&P 500 (4W)2.73%

VGM Score30.59

Market Capitalization$6.82M

All Metrics

Book Value / Share (Quarterly)$36.20

P/TBV (Annual)1.31x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-22.55

Price vs S&P 500 (YTD)-17.04%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-5483.33%

EPS (TTM)$-31.33

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-31.33

EPS (Annual)$-1.29

ROI (Annual)-52.18%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-7032.74%

Cash / Share (Quarterly)$38.00

ROA (Last FY)-48.94%

EBITD / Share (TTM)$-32.74

ROE (5Y Avg)-65.39%

Operating Margin (TTM)-4461.11%

Cash Flow / Share (Annual)$-23.74

P/B Ratio0.29x

P/B Ratio (Quarterly)0.28x

Net Income / Employee (Annual)$-666,700

Net Interest Coverage (TTM)-117.55x

ROA (TTM)-60.42%

EPS Incl Extra (Annual)$-1.29

Current Ratio (Annual)13.58x

Quick Ratio (Quarterly)11.63x

3-Month Avg Trading Volume0.02M

52-Week Price Return-92.07%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.63

P/S Ratio (Annual)227.23x

Asset Turnover (Annual)0.01x

52-Week High$196.70

Operating Margin (5Y Avg)-6266.24%

EPS Excl Extra (Annual)$-1.29

CapEx CAGR (5Y)-51.16%

26-Week Price Return-14.20%

Quick Ratio (Annual)13.29x

13-Week Price Return-5.33%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.89x

Enterprise Value$4.22M

Asset Turnover (TTM)0.03x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-25433.33%

Cash / Share (Annual)$43.01

3-Month Return Std Dev69.00%

Net Income / Employee (TTM)$-570,200

ROE (Last FY)-52.18%

Net Interest Coverage (Annual)-87.25x

EPS Basic Excl Extra (Annual)$-1.29

Receivables Turnover (TTM)2.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-31.33

Receivables Turnover (Annual)2.00x

ROI (TTM)-66.39%

P/S Ratio (TTM)37.87x

Pretax Margin (5Y Avg)-7056.77%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$4.09

Price vs S&P 500 (52W)-116.44%

Year-to-Date Return-9.08%

5-Day Price Return-4.34%

EPS Normalized (Annual)$-1.29

ROA (5Y Avg)-54.58%

Net Profit Margin (Annual)-25433.33%

Month-to-Date Return-9.89%

Cash Flow / Share (TTM)$-2.12

EBITD / Share (Annual)$-1.40

Operating Margin (Annual)-25600.00%

ROI (5Y Avg)-64.31%

EPS Basic Excl Extra (TTM)$-31.33

P/TBV (Quarterly)2.03x

P/B Ratio (Annual)0.24x

Inventory Turnover (TTM)9.33x

Pretax Margin (TTM)-5483.33%

Book Value / Share (Annual)$41.36

Price vs S&P 500 (13W)-13.59%

Beta1.09x

P/FCF (Annual)75.74x

Revenue / Share (TTM)$0.00

ROE (TTM)-66.39%

52-Week Low$8.67

mGradeD

vgmGradeD

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

2.17

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
NVNOenVVeno Medical Corporation Common Stock	—	—	D	$10.21
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

enVVeno Medical Corp develops bioprosthetic venous valve replacements to treat venous disease. The company's lead product, VenoValve, is a surgical replacement currently in a U.S. pivotal trial, while its pipeline includes enVVe, a non-surgical transcatheter option. Both products are designed to restore valve function and improve blood circulation in the legs.